Dr. John Cush RheumNow
5 years 4 months ago
Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021
https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK
Aurelie Najm AurelieRheumo
5 years 4 months ago
DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl
Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue
signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 https://t.co/7WChCP3U6W
Eric Dein ejdein1
5 years 4 months ago
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed
Md Yuzaiful Md Yusof Yuz6Yusof
5 years 4 months ago
Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results from Phase III COSMOS. 44.4% of GUS-treated vs 19.8% Placebo-tx achieved ACR20 response at Wk24 (p<0.001). Well tolerated and No major safety #EULAR2021 #OP0230 @RheumNow https://t.co/EuGaacSuxF
Richard Conway RichardPAConway
5 years 4 months ago
Zara Izadi presents @rheum_covid data on machine learning algorithms to predict ARDS in RMD patients with COVID. Gradient boosting machine had 81% sensitivity to predict ARDS from baseline data @RheumNow #EULAR2021 Abstr#OP0288 https://t.co/tHlPzeX9He
Dr. John Cush RheumNow
5 years 4 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
5 years 4 months ago
Check out our Lupus content from #EULAR2021 at RheumNow.
https://t.co/Gmh4sFv4Jl https://t.co/yBkbeMn0Yd
Paul Studenic Stiddyo
5 years 4 months ago
#OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16weeks
Primary endpoint ACR20
12mg: 62.7%
6mg: 52.9%
PLC: 31.8%
+ well tolarated: no serious adverse events
#EULAR2021 @RheumNow https://t.co/6SFqWd79db
Dr. Rachel Tate uptoTate
5 years 4 months ago
Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have ⬇️ with TNFi over the past 20 years. TNFi retention rates have ⬇️ while remission rates have ⬆️ (notably those in 1st yr tx) #EULAR2021 @RheumNow https://t.co/gnKRfvbHPQ https://t.co/PRunGIxMwx
Robert B Chao, MD doctorRBC
5 years 4 months ago
IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy?
⭐️Phase II study - no difference in rotator cuff score (WORC) vs placebo
⭐️no difference in pain score
Abs#POS0022
#EULAR2021 @RheumNow
David Liew drdavidliew
5 years 4 months ago
Pregnancy is a minefield for RA pts:
dx activity➡️preg risk
PNL➡️preg risk, but dx activity proxy?
bring on Swedish/Danish linked data:
1739 RA preg matched 1:10
⬆️pre-term/SGA risk with bDMARDs/PNL
adj for dx activity: less bad, but still concern?
OP0210 #EULAR2021 @RheumNow https://t.co/AlwFtmGcZH
Janet Pope Janetbirdope
5 years 4 months ago
Ever wonder why one drug works in a pt & not another? Study of bio markers in PsA from RCT of #upadacitinib vs #adalimumab shows diff pathways affected by each drug & some overlap too @RheumNow #EULAR2021 @eular_org OP0030 https://t.co/WifrVOIMkW
Dr. Rachel Tate uptoTate
5 years 4 months ago
UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity and damage scores could be used in observational and controlled trials.
#EULAR2021 @RheumNow https://t.co/Tw7OWyMcgX https://t.co/WiT0yGwVqK
Aurelie Najm AurelieRheumo
5 years 4 months ago
In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy associated w/ less DAS28 ESR Remission at 5 (45.0% in vs. 56.3% (p=0.03)) and 10 yrs (32.5% vs. 67.5% (p=0.06)) BUT no longer significant when adjusted for comorbidities!
#EULAR2021 @Rheumnow #OP0098 https://t.co/pSrr1dzKFP
